iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) Sets New 12-Month High – Should You Buy?

iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) reached a new 52-week high on Tuesday . The stock traded as high as $100.14 and last traded at $100.13, with a volume of 313962 shares trading hands. The stock had previously closed at $99.13.

iShares U.S. Pharmaceuticals ETF Price Performance

The company has a market capitalization of $1.08 billion, a PE ratio of 17.75 and a beta of 0.50. The company has a 50 day moving average of $90.71 and a two-hundred day moving average of $88.35.

Institutional Trading of iShares U.S. Pharmaceuticals ETF

A number of hedge funds have recently modified their holdings of the business. EFG International AG purchased a new stake in iShares U.S. Pharmaceuticals ETF in the fourth quarter worth about $38,000. Assetmark Inc. lifted its holdings in shares of iShares U.S. Pharmaceuticals ETF by 203.9% during the fourth quarter. Assetmark Inc. now owns 465 shares of the company’s stock valued at $39,000 after purchasing an additional 312 shares during the last quarter. O Shaughnessy Asset Management LLC lifted its holdings in shares of iShares U.S. Pharmaceuticals ETF by 35.0% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 463 shares of the company’s stock valued at $39,000 after purchasing an additional 120 shares during the last quarter. Blueline Advisors LLC purchased a new position in shares of iShares U.S. Pharmaceuticals ETF during the fourth quarter valued at approximately $41,000. Finally, Ameriflex Group Inc. boosted its position in shares of iShares U.S. Pharmaceuticals ETF by 100.0% in the 3rd quarter. Ameriflex Group Inc. now owns 582 shares of the company’s stock worth $42,000 after purchasing an additional 291 shares in the last quarter.

About iShares U.S. Pharmaceuticals ETF

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.